Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended Letermovir Prophylaxis in HSCT Recipients
NCT03930615Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2019
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of letermovir in cytomegalovirus infection (CMV), sponsored by Merck & Co.. Started Jun 2019; status: completed.
02
Drugs
letermovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT03930615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03930615.